How to Start Intermittent Fasting
To start intermittent fasting, pick a schedule you can sustain and begin gradually rather than jumping to the longest window; research reports mild to moderate weight loss and improved metabolic markers over weeks to months.
Medical caution
This is general information about fasting, not medical advice. Fasting can affect blood sugar, blood pressure, medication timing, and nutritional status. Talk to a clinician before starting or changing a fasting practice if you are pregnant, under 18, living with diabetes or another chronic condition, taking prescription medication, or have a history of an eating disorder.
Choose a Schedule That Fits Your Life
Several named approaches show up across the research: a daily 16:8 or 14:10 eating window, alternate-day fasting, a 5:2 pattern of two reduced-calorie days a week, and one-meal-a-day (OMAD) eating. None of these schedules has been shown to be clearly superior to the others for most people; in people with type 2 diabetes specifically, a network meta-analysis of 13 trials found no significant difference in effect between four fasting regimens, with twice-weekly fasting ranking best, not the more commonly recommended 16:8 (Xiaoyu, Yuxin, and Li, 2024) [11]. The practical starting point is a schedule sustainable enough to stick with, begun gradually rather than jumping straight to the longest window.
What the Research Shows About Weight and Metabolic Health
The largest body of evidence to date, a 2025 systematic review and network meta-analysis of 99 randomized trials in 6,582 adults, found that both intermittent fasting and continuous calorie restriction reduce body weight compared with an unrestricted diet, with alternate-day fasting showing the largest edge among the intermittent-fasting variants studied (Semnani-Azad et al., 2025) [1]. A systematic review of 27 smaller, mostly short trials (2 to 26 weeks, two running a year) found weight loss of 0.8% to 13.0% of baseline body weight, no serious adverse events, and results broadly similar to calorie restriction; five of those trials included people with type 2 diabetes and all five reported improved glycemic control (Welton et al., 2020) [2]. A separate review of alternate-day fasting, 5:2, and time-restricted eating more broadly reports mild to moderate weight loss (roughly 1% to 8% of baseline) and a consistent reduction in energy intake, and notes intermittent fasting may also improve blood pressure, insulin resistance, and oxidative stress markers, with no evidence in the trials it reviewed of increased disordered eating behavior (Varady et al., 2021) [3].
In people with obesity and type 2 diabetes, a three-month randomized trial of 16:8 fasting three days a week produced a larger weight change than a control group, with improved fasting blood sugar, HbA1c, and lipids (Sukkriang and Buranapin, 2024) [4]. In people with insulin-treated type 2 diabetes, a 12-week supervised trial with dietary counseling and continuous glucose monitoring improved HbA1c and reduced insulin dose without severe hypoglycemia (Obermayer et al., 2023) [5], and a three-week trial in adults with prediabetes found both alternate-day fasting and 16:8 reduced weight, BMI, waist circumference, blood glucose, and triglycerides, with alternate-day fasting outperforming 16:8 on weight and BMI specifically (Chair et al., 2022) [6].
That is the supportive side of the evidence. It is not the whole picture: see "Where the studies disagree" in the evidence box below for the findings that complicate a simple "intermittent fasting works" summary, including a one-year trial that found no advantage for alternate-day fasting over calorie restriction, two randomized trials that found no weight-loss benefit from time-restricted eating over calorie restriction specifically, and two separate evidence-quality reviews rating most of this literature as low to very low certainty.
How Long Before You See a Change
Most of the trials behind these findings ran from a few weeks to several months, in adults who were already overweight or managing an existing metabolic condition, so "how long" is better read as "how long in these specific trials" than as a universal timeline. Short trials of three to twelve weeks report measurable changes in weight and glycemic markers (Chair et al., 2022 [6]; Obermayer et al., 2023 [5]), while the longer, one-year head-to-head trial found weight loss plateaued at similar levels for alternate-day fasting and daily calorie restriction by six months (Trepanowski et al., 2017) [7]. A recurring finding worth factoring into any timeline expectation: lean or fat-free mass loss shows up alongside fat loss in more than one trial (Lowe et al., 2020 [8]; Patikorn et al., 2021 [10]), so "how long before you see a change" is not only a question about the scale. Over a longer timeline, a 12-month trial of time-restricted eating with calorie restriction found no significant difference in weight loss or metabolic risk factors against calorie restriction alone by the end of that year (Liu et al., 2022) [12].
Getting Started, Step by Step
Start with a shorter eating window, such as 12:12, and extend it gradually toward a schedule like 16:8 rather than beginning at the longest window attempted. Pay attention to hydration and electrolytes during the fasting window; full detail on that lives on the water fasting page, since the same principles apply at longer durations. Plan the first meal back deliberately rather than as an afterthought; see the refeeding guide for how to do that safely, particularly after a longer fast.
What Breaks a Fast While You're Doing This
Coffee, gum, electrolytes, and medication timing all raise the same practical question: does this end the fasted state? See what breaks a fast for a detailed, cited answer to each.
Who Should Talk to a Clinician First
People on insulin or sulfonylureas should only fast under clinician supervision; the favorable safety result in the insulin-treated trial above came from a protocol with monitoring built in, which is evidence that intermittent fasting can be done safely on insulin, not evidence that it is safe to do unsupervised (Obermayer et al., 2023) [5]. Pregnancy, a history of an eating disorder, being under 18, and any chronic condition requiring consistent food or medication timing are reasons to get clinician guidance before starting, as a matter of general clinical caution rather than a specific finding from these trials.
Common Questions
Most of the named schedules (16:8, 5:2, alternate-day fasting, OMAD) have not been shown to clearly outperform one another in head-to-head evidence; pick one that fits your routine. This holds even in a specific head-to-head comparison: a network meta-analysis in people with type 2 diabetes found no significant difference between four fasting regimens, including the fasting-mimicking diet (Xiaoyu, Yuxin, and Li, 2024) [11]. The evidence quality behind most intermittent-fasting health claims is rated low to very low certainty by the two separate reviews with the most rigorous methodology in this set (Allaf et al., 2021 [9]; Patikorn et al., 2021 [10]), so claims of dramatic or guaranteed results should be treated with skepticism.
Safety and Cautions
This is general information, not medical advice. A recurring signal across this literature is some loss of lean or fat-free mass alongside fat loss, not a one-off finding (Lowe et al., 2020 [8]; Patikorn et al., 2021 [10]). Most of the supportive evidence above comes from short trials in adults who were already overweight or managing a metabolic condition; it should not be read as durable, universal results for everyone. Talk to a clinician before starting if pregnant, under 18, managing diabetes with insulin or sulfonylureas, or with a history of an eating disorder.
What the evidence actually supports
Pooled across many trials, intermittent fasting produces mild to moderate weight loss, roughly on par with ordinary calorie restriction, with alternate-day fasting showing a small edge over daily calorie restriction in the largest network meta-analysis to date (Semnani-Azad et al., 2025) [1]. Smaller and shorter trials report weight loss with no serious adverse events, with results roughly equivalent to calorie restriction (Welton et al., 2020) [2]. Across alternate-day fasting, 5:2, and time-restricted eating more broadly, a separate review reports a consistent reduction in energy intake, and notes that intermittent fasting may also improve blood pressure, insulin resistance, and oxidative stress markers (Varady et al., 2021) [3]. In people with type 2 diabetes, structured intermittent fasting protocols run under clinical supervision have improved fasting glucose, HbA1c, and lipids (Sukkriang and Buranapin, 2024) [4], and, in people on insulin, improved HbA1c without severe hypoglycemia when monitored closely (Obermayer et al., 2023) [5]. A short trial in adults with prediabetes found similar benefits over three weeks (Chair et al., 2022) [6]. In people with type 2 diabetes specifically, a network meta-analysis of 13 trials comparing four different fasting regimens, including the fasting-mimicking diet, found all four improved glucose control versus a conventional diet, but found no significant difference between the four regimens themselves (Xiaoyu, Yuxin, and Li, 2024) [11]; no single schedule stood out as the best choice.
Where the studies disagree
A 2025 network meta-analysis pooling many trials found alternate-day fasting modestly outperforms daily calorie restriction (Semnani-Azad et al., 2025) [1], but a dedicated, longer, one-year head-to-head randomized trial found no advantage for alternate-day fasting on weight loss, maintenance, or adherence, and a worse LDL cholesterol signal by month 12 (Trepanowski et al., 2017) [7]. The summary is that alternate-day fasting is not clearly superior to ordinary calorie restriction for most people, and may be harder to sustain. That same network meta-analysis found time-restricted eating beats an unrestricted diet but not ordinary calorie restriction (Semnani-Azad et al., 2025) [1], and two purpose-built randomized trials testing time-restricted eating head-to-head against ordinary meal timing or calorie restriction agree with that null result: a 12-week trial in 116 adults found no weight-loss advantage and a significant reduction in lean mass in the time-restricted group (Lowe et al., 2020) [8], and a 12-month trial in 139 adults with obesity found no significant difference in weight loss between time-restricted eating with calorie restriction and calorie restriction alone (Liu et al., 2022) [12]. The most rigorous evidence-quality reviews available rate almost all of this literature as low to very low certainty: a Cochrane review found the weight reduction from intermittent fasting, versus ad-libitum eating, was not clinically significant, with no study reporting on mortality, stroke, or heart attack at any follow-up (Allaf et al., 2021) [9]; an umbrella review of 11 meta-analyses found only 1% of 104 intermittent-fasting health-outcome findings were backed by high-quality evidence, with reduced fat-free mass showing up as a recurring pattern (Patikorn et al., 2021) [10]. In people with type 2 diabetes, a network meta-analysis of 13 trials found no significant difference between four fasting regimens, with twice-weekly fasting, not the more commonly recommended 16:8, ranking best on a composite score (Xiaoyu, Yuxin, and Li, 2024) [11]. Intermittent fasting schedules can produce mild to moderate weight loss for many people, roughly on par with calorie restriction and with each other, not clearly superior to either, with a recurring, though not universal, signal of some lean-mass loss alongside fat loss, not a settled, high-certainty finding that any one schedule beats the rest.
References
- Semnani-Azad Z, Khan TA, Chiavaroli L, Chen V, Bhatt HA, Chen A, Chiang N, Oguntala J, Kabisch S, Lau DC, Wharton S, Sharma AM, Harris L, Leiter LA, Hill JO, Hu FB, Lean ME, Kahleová H, Rahelic D, Salas-Salvadó J, Kendall CW, Sievenpiper JL (2025). Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors, systematic review and network meta-analysis of randomised clinical trials. BMJ. PMID 40533200 doi:10.1136/bmj-2024-082007 Finding: supports
- Welton S, Minty R, O'Driscoll T, Willms H, Poirier D, Madden S, Kelly L (2020). Intermittent fasting and weight loss, systematic review. Canadian Family Physician. PMID 32060194 Finding: limited evidence
- Varady KA, Cienfuegos S, Ezpeleta M, Gabel K (2021). Cardiometabolic Benefits of Intermittent Fasting. Annual Review of Nutrition. PMID 34633860 doi:10.1146/annurev-nutr-052020-041327 Finding: limited evidence
- Sukkriang N, Buranapin S (2024). Effect of intermittent fasting 16:8 and 14:10 compared with control group on weight reduction and metabolic outcomes in obesity with type 2 diabetes patients, a randomized controlled trial. Journal of Diabetes Investigation. PMID 38932663 doi:10.1111/jdi.14186 Finding: supports
- Obermayer A, Tripolt NJ, Pferschy PN, Kojzar H, Aziz F, Müller A, Schauer M, Oulhaj A, Aberer F, Sourij C, Habisch H, Madl T, Pieber T, Obermayer-Pietsch B, Stadlbauer V, Sourij H (2023). Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes, INTERFAST-2, a Randomized Controlled Trial. Diabetes Care. PMID 36508320 doi:10.2337/dc22-1622 Finding: supports
- Chair SY, Cai H, Cao X, Qin Y, Cheng HY, Ng MT (2022). Intermittent Fasting in Weight Loss and Cardiometabolic Risk Reduction, a Randomized Controlled Trial. Journal of Nursing Research. PMID 35050952 doi:10.1097/jnr.0000000000000469 Finding: supports
- Trepanowski JF, Kroeger CM, Barnosky A, Klempel MC, Bhutani S, Hoddy KK, Gabel K, Freels S, Rigdon J, Rood J, Ravussin E, Varady KA (2017). Effect of Alternate-Day Fasting on Weight Loss, Weight Maintenance, and Cardioprotection Among Metabolically Healthy Obese Adults, a Randomized Clinical Trial. JAMA Internal Medicine. PMID 28459931 doi:10.1001/jamainternmed.2017.0936 Finding: contradicts
- Lowe DA, Wu N, Rohdin-Bibby L, Moore AH, Kelly N, Liu YE, Philip E, Vittinghoff E, Heymsfield SB, Olgin JE, Shepherd JA, Weiss EJ (2020). Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity, the TREAT Randomized Clinical Trial. JAMA Internal Medicine. PMID 32986097 doi:10.1001/jamainternmed.2020.4153 Finding: contradicts
- Allaf M, Elghazaly H, Mohamed OG, Fareen MFK, Zaman S, Salmasi AM, Tsilidis K, Dehghan A (2021). Intermittent fasting for the prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. PMID 33512717 doi:10.1002/14651858.CD013496.pub2 Finding: contradicts
- Patikorn C, Roubal K, Veettil SK, Chandran V, Pham T, Lee YY, Giovannucci EL, Varady KA, Chaiyakunapruk N (2021). Intermittent Fasting and Obesity-Related Health Outcomes, an Umbrella Review of Meta-analyses of Randomized Clinical Trials. JAMA Network Open. PMID 34919135 doi:10.1001/jamanetworkopen.2021.39558 Finding: limited evidence
- Xiaoyu W, Yuxin X, Li L (2024). The effects of different intermittent fasting regimens in people with type 2 diabetes, a network meta-analysis. Frontiers in Nutrition. PMID 38332802 doi:10.3389/fnut.2024.1325894 Finding: no effect found
- Liu D, Huang Y, Huang C, Yang S, Wei X, Zhang P, Guo D, Lin J, Xu B, Li C, He H, He J, Liu S, Shi L, Xue Y, Zhang H (2022). Calorie Restriction with or without Time-Restricted Eating in Weight Loss. New England Journal of Medicine. PMID 35443107 doi:10.1056/NEJMoa2114833 Finding: contradicts